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Suzuki reaction of aryl halides with organo-
boron offers a facile synthetic route to synthesize
biaryls (1-2). This cross-coupling reaction is typi-
cally attractive and beneficial for the construction of
C-C bonds due to number of reasons such as high
functional group tolerance, favorable reaction kinet-
ics and easy handling of non-hazardous by-products
(1-5). The Biaryl motifs are important substructures
in pharmaceuticals as anti-arthritic, cholesterol inhi-
bition, anti-leukemic activities. These are also
potentially useful in agrochemicals, energy and
functional materials (6-7). Therefore, the synthesis
of novel biaryls with the unique therapeutic features
is gaining significant attention from the scientific
community working in the development of new
drugs. In view of the medicinal importance of bia-
ryls, the present research was carried out to synthe-
size the various functionalized biaryl derivatives via
Palladium (Pd) catalyzed Suzuki coupling reaction.
In addition to the synthesis, we have also investiga-
ted the potential pharmaceutical applications of the
newly synthesized biaryls to combat various ail-
ments.
MATERIALS AND METHODS
General
Melting point apparatus (B-540) was used for
determining the melting points of synthesized
solids. 1H-NMR was measured using CDCl3 (Bruker
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ARX at 300, 400, 500, 600 MHz). JMS-HX-110
spectrometer with a data system was used for EI-MS
spectra. For column chromatography, silica gel
(70ñ230 and 230ñ400 mesh) was used. TLC was
used for monitoring the completion of reaction,
(Merck silica gel 60 PF254 cards) and the visualiza-
tion of compounds was done by UV lamp (254-365
nm).
General procedure for the synthesis of intermedi-
ate compound 4-bromo-2-chloro-1-(prop-2-yn-1-
yloxy)benzene (2)
4-Bromo-2-chlorophenol (1.0 g, 4.83 mmol),
propargyl bromide (0.688 g, 5.78 mmol), potassium
carbonate (K2CO3) (2.33 g, 16.8 mmol) and 15 mL
of dry acetone was added into Schlenk flask. Then it
was refluxed at 80OC for 5 h. After that Schlenk flask
cooled at room temperature. Completion of the reac-
tion was monitored by TLC followed by the addition
of distilled H2O (10 mL) and dichloromethane (10
mL DCM). The organic layer was separated and the
remaining moisture from organic layer was removed
by using Sodium sulphate (Na2SO4). After filtration
and subsequent evaporation, the product was puri-
fied by flash chromatography. Mixture of n-hexane
and ethyl acetate was used as eluent (8).
General procedure for the synthesis of biaryl
compounds (3a-g)
A mixture containing Phenol (2) (0.250 mg,
1.09 mmol), tetrakis-triphenylphosphine palladium
(0.027 g, 2.5 mol%) as catalyst and 1,4-dioxane (2.5
mL) was taken in the Schlenk flask, followed by
stirring at room temperature for 20 min in presence
of inert atmosphere. To this mixture, respective
arylboronic acid (1.54 mmol) together with a known
amount of potassium phosphate (K3PO4) and water
(0.625 mL) were added to a reaction flask. This
reaction mixture was again stirred at 80-90OC for 15
h. After cooling the reaction mixture, it was further
diluted with ethyl-acetate and distilled water. The
organic layer was separated using a separating fun-
nel and sodium sulfate was used to remove the
remaining moisture content. The mixture was fur-
ther concentrated and dried by using rota-vapour.
The obtained residue was purified by the column
chromatography using a mixture of ethyl acetate and
n-hexane as an eluent.
Characterization data
4-Bromo-2-chloro-1-(prop-2-yn-1-yloxy)benzene
(2) 
Obtained as solid, mp = 516OC. 1H-NMR
(CDCl3, 600 MHz) δ: 7.51 (d, J1,3 = 2.4 Hz, 1H),
7.33-7.18 (m, 1H), 6.95 (d, J1,2 = 8.4 Hz, 1H), 4.74
(d, J1,3 = 2.4 Hz, 2H), 2.53-2.52 (m, 1H). 13C NMR
(CDCl3, 150 MHz, δ, ppm): 150.1, 130.0 (m), 121.2,
118.0, 116.1, 78.7, 75.1, 54.1. EI/MS (m/z, + ion
mode): [M+]+ = 246 [M+2]+ = 248, [M+4]+ = 250.
3-Chloro-3,5í-dimethyl-4-(prop-2-yn-1-yloxy)-
1,1í-biphenyl (3a)
Obtained as solid, mp = 484OC. 1H-NMR
(CDCl3, 600 MHz) δ: 7.51 (d, J1,3 = 1.8 Hz, 1H), 7.37
(dd, J1,2 = 8.4 Hz, J1,3 = 2.4 Hz, 1H), 7.11 (br.s, 1H),
7.04 (d, J1,2 = 8.4 Hz, 2H), 6.95 (br.s, 1H), 3.47 (s,
2H), 2.40 (br.s, 1H), 2.34 (s, 6H), 13C NMR (CDCl3,
150 MHz, δ, ppm): 21.3, 22.0, 54.2, 76.1, 78.9,
115.3, 122.6, 125.0, 126.3, 128.4, 129.2, 133.4,
138.2, 138.9, 142.9, 153.6. EI/MS (m/z, + ion
mode): [M+]+ = 271, [M+2]+ = 273.
3-Chloro-3,5í-diflouro-4-(prop-2-yn-1-yloxy)-
1,1í-biphenyl (3b)
Obtained as solid, mp = 460OC. 1H-NMR (400
MHz, CDCl3) δ: 7.67-7.62 (m, 2H), 7.33 (dd, J1,2 =
8.4, J1,3 = 2.0 Hz, 1H), 7.08 (d, J1,2 = 8.4 Hz, 1H),
7.01 (d, J1,2 = 6.4 Hz, 1H), 6.74 (t, J2(1,3) = 8.8 Hz,
1H), 4.43 (s, 2H), 3.58 (s, 1H). 13C NMR (CDCl3,
100 MHz, δ, ppm): 58.2, 76.2, 79.7, 119.0 (m),
101.2, 116.9, 122.0, 125.6, 130.9, 134.9, 140.1,
152.0, 165.8 (m) 167.0 (m). EI/MS (m/z, + ion
mode): [M+]+ = 279.2, [M+2]+ = 281.
3-Chloro-4í-methyl-[1,1í-biphenyl]-4-ol (3c)
Obtained as solid, mp = 454OC. 1H-NMR (300
MHz, CDCl3) δ: 7.52 (d, J1,3 = 3.0 Hz, 1H), 7.40-
7.36 (m, 3H), 7.22-7.20 (m, 2H), 7.05 (d, J1,2 = 9.0
Hz, 1H), 2.36 (s, 3H). 13C NMR (CDCl3, 75 MHz, δ,
ppm): 22.0, 116.2, 123.1, 126.2, 127.8, 129.0, 129.8,
130.1, 130.8, 132.1, 139.0, 152.9. EI/MS (m/z, + ion
mode): [M]+ = 218.0, [M+2]+ = 220. 
3-Chloro-4í-methoxy-[1,1í-biphenyl]-4-o l(3d)
Obtained as solid, mp = 475OC. 1H-NMR (600
MHz, CDCl3) δ: 7.48 (d, J1,2 = 2.4 Hz, 1H), 7.43-
7.40 (m, 2H), 7.34 (dd, J1,2 = 8.4, J1,3 = 2.4 Hz, 1H),
7.04 (d, J1,2 = 8.4 Hz, 1H), 6.95-6.93 (m, 2H), 3.82
(s, 3H). 13C NMR (CDCl3, 150 MHz, δ, ppm): 53.2,
112.3, 114.2, 118.2, 124.3, 128.9, 131.0, 132.9,
133.2, 135.6, 156.2, 159.2. EI/MS (m/z, + ion
mode): [M+]+ = 234.0, [M+2]+ = 236.
3,4í-Dichloro-[1,1í-biphenyl]-4-ol (3e)
Obtained as solid, mp = 575OC.1H-NMR (300
MHz, CDCl3) δ: 7.50 (d, J1,2 = 3.0 Hz, 1H), 7.44-
7.33 (m, 2H), 7.06 (d, J1,2 = 9.0 Hz, 2H), 6.98-6.71
(m, 2H). 13C NMR (CDCl3, 75 MHz, δ, ppm): 116.2,
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124.3, 126.7, 128.3, 129.1, 129.6, 129.6, 130.1,
134.2, 136.1, 138.9, 151.0. EI/MS (m/z, + ion
mode): [M+]+ = 238.0, [M+2]+ = 240, [M+4]+ =
242.0.
1-(3í-Chloro-4í-hydroxy-[1,1í-biphenyl]-3-yl)eth-
anone (3f)
Obtained as solid, mp = 516OC. 1H-NMR (600
MHz, CDCl3) δ: 8.04 (d, J1,2 = 7.2 Hz, 1H), 7.97 (d,
J1,2 = 7.2 Hz, 1H), 7.53(t, J2(1,3) = 7.2 Hz, 1H), 7.50-
7.43 (m, 3H), 2.62 (s, 3H). 13C NMR (CDCl3, 150
MHz, δ, ppm): 27.0, 116.5,125.6, 127.8, 127.9,
128.9, 129.0, 129.9, 131.2, 134.0, 136.7, 143.3,
156.0, 198.0. EIMS (m/z, + ion mode): [M+]+ = 246,
[M+2]+ = 248.
3-Chloro-4í-(methylthio)-[1,1í-biphenyl]-4-ol
(3g)
Obtained as solid, mp = 516OC. 1H-NMR (600
MHz, CDCl3) δ: 7.48-7.45 (m, 2H), 7.42 (d, J1,2 =
8.4 Hz, 1H), 7.36 (d, J1,2 = 8.4, J1,3 = 2.4 Hz, 1H),
7.29 (d, J1,2 = 7.2 Hz, 1H), 7.05 (d, J1,2 = 8.4 Hz, 2H),
2.53 (s, 3H).13C NMR (CDCl3, 150 MHz, δ, ppm):
15.6, 115.6, 123.4, 126.7, 127.3, 128.1, 128.9,
129.2, 129.9, 133.2, 138.2, 139.0, 150.9. EI/MS
(m/z, + ion mode): [M+]+ = 250, [M+2]+ = 252.
Computational methods
All calculations were performed by using
Gaussian 09 software (9) and graphics were analyzed
with the help of Gauss view 05 (10). Geometries of the
transition states and intermediate products were opti-
mized without any symmetry constraints by imple-
menting a hybrid B3LYP method which provides nice
balance between computational cost and accuracy
(11-12). For geometries optimization, 6-31G (d) (13,
14) basis set was used for C, H, O, B, Br and Cl atoms
and LANL2DZ pseudo potential was used for Pd
atom. Every optimized geometry was confirmed by
frequency analysis at the same level as a true mini-
mum (no imaginary frequency) or as a transition state
(with one imaginary frequency). The reported ener-
gies for all mechanistic steps are in kcal mol-1.
Pharmacology
Biofilm inhibition assay by microtitre plate method
The novel biaryl derivatives were examined for
their biofilm inhibition activity (15), where Ethyl-
acetate was used for preparing solutions of test sam-
ples. In brief, the sample solution (100 µL) (3añg),
nutrient broth (100 µL) and the 20 µL of bacterial
suspension were inoculated in 96-well plates.
Rifampicin and nutrient broth were used as positive
and negative controls, respectively. The incubation
of well plates was done at 37OC for 24 h. Each plate
was washed thrice by Phosphate-buffer solution
(PBS) (220 µL), followed by shaking to remove
adherent bacteria. The 95% methanolic solution
(220 µL) was used to fix remaining bacteria from
well plates, followed by oven drying. 
Scheme 1. Synthesis of intermediate compound 4-bromo-2-chloro-1-(prop-2-yn-1-yloxy)benzene (2) and Suzuki cross coupling of (2) with
various aryl boronic acids. Conditions: (i), 1 (1 g, 4.83 mmol), propargylbromide (0.68 g, 5.78 mmol), potassium carbonate (K2CO3) (2.33
g, 16.8 mmol), 80∫C, dry acetone, reflux 5 h. (ii), 2 (0.1 g, 1 eq, 0.38 mmol), ArB(OH)2 (1.1 eq, 0.71 mmol), K3PO4 (0.21 g, 1.02 mmol),
Pd(PPh3)4 (0.011 g, 2.5 mol%), 1,4-dioxane: H2O (4 : 1), reflux 18 h, 90OC
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For staining the plates, crystal violet (220 µL)
was used (50% concentration) for 5 min. Excess
stain was removed by tap water from these plates.
For removing the remaining dye attached with cells,
glacial acetic acid (220 µL) (33% concentration)
was used. OD value of each well was examined with
the help of the microplate reader (BioTek,
Winooski, VT, USA) at 630 nm.
The Biofilm inhibition was quantified by
measuring OD540 using the following expression:
Assay of hemolytic activity
The cytotoxicity of novel biaryl compounds
(3a-g) was also tested using the previously reported
method (16). In a typical procedure, a known
amount of human blood (heparinized, 3 mL) was
collected from the volunteers, which was cen-
trifuged at 1000 rpm for 5 min. After discarding the
plasma, chilled 5 mL (4OC) Phosphate-buffer saline
(PBS) (pH ~7.4) was used to wash the cells thrice.
For each assay, erythrocytes were maintained (108
cells/ mL). After that, the synthesized compounds
(100 µL) were mixed with blood cells separately
and then the incubation of samples was done at
37OC for 35 min followed by agitation for 10 min.
After incubation (for 5 min), the samples were fur-
ther kept on ice, followed by centrifuge process
(100 rpm for 5 min). The chilled buffer solution
(4OC) was used for 10 times dilution of supernatants
from each tube. As a positive control, the Triton 
X-100 (0.1% v/v) and as a negative control, the phos-
phate buffer saline (PBS) was used. Later on, the
absorbance of the test solution was measured at 576
nm by using µ Quant (Biotek, USA). The percent-
age (%) lysis of RBCs of every sample was calcu-
lated accordingly.
Analysis of Anti-Thrombolytic activity
After the consent of healthy volunteers, the
blood samples were collected accordingly. In the
weighed micro-centrifuge, the blood (100 mL)
was added to form the clots. Then in micro-tubes,
the solution (100 µL) of the novel synthesized
compounds with particular a concentration (1
mg/mL) was added, and incubation was done
(37OC for 45 min). Streptokinase and deionized
water were used as positive and negative controls
respectively (16).
RESULTS AND DISCUSSION
Chemistry
The protection of aromatic amino or hydroxyl
groups in the form of amine derivatives or ethers
Table 1. Substrate scope of Suzuki coupling of 4-bromo-2-chloro-1-(prop-2-yn-1-yloxy)benzene with variety
of arylboronic acids.
OD growth control ñ OD sample control
% Biofilm inhibition = ññññññññññññññññññññññññññññññññññññ × 100
OD growth control
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and their subsequent cleavage constitute a useful
chemical transformation in organic synthesis. The
presence of two orthogonal π-bonds in propargyl
group further makes it attractive, which perhaps
help in its facile cleavage in the presence of transi-
tion metal complexes (17-18).
In the present research work, we investigated
the Suzuki reaction of 4-bromo-2-chloro-1-(prop-2-
yn-1-yloxy)benzene (2) with different aryl boronic
acids under optimal conditions. According to our
survey, to date no such study has been reported on
the synthesis and biological activities of various
derivatives (3a-g) of 4-bromo-2-chloro-1-(prop-2-
yn-1-yloxy)benzene. As presented in the Scheme 1,
the first step is the synthesis of intermediate com-
pound 4-bromo-2-chloro-1-(prop-2-yn-1-yloxy)
Figure 1. Energy profile for three major steps of the Suzuki coupling at Br position starting from Int1A (all values are in kcal mol-1)
Figure 2. Energy profile for three major steps of the Suzuki coupling at Cl position starting from Int1B (all values are in kcal mol-1)
916 HIRA FAROOQ et al.
benzene (2), which was obtained in 90% yield from
the reaction between 4-bromo-2-chlorophenol (1)
and propargyl bromide (Scheme 1). In general, the
aryl halides which are substituted with electron-
withdrawing groups are appropriate substrates for
the cross-coupling reaction (19). Since the hydroxyl
group attached with the phenyl ring has electron
donating ability, we first protected the -OH group
before carrying out the Suzuki cross-coupling reac-
tion.
In the second step, Suzuki coupling of (2) with
various arylboronic acids was conducted that even-
tually led to the synthesis of various biaryl deriva-
tives (3a-g) in high yields (80-88%) (Table 1). The
Biaryl Compounds 3a and 3b were obtained with
protected ether group; while compounds 3c-3g were
de-propargylated to corresponding phenol in the
reaction mixture.
In past, the Palladium catalyzed depropargyla-
tion (cleavage of C-O propargyl bond) of aryl
propargyl ethers cleaved to the corresponding phe-
nol has already been reported (17, 20). Various sub-
stituents on the phenyl ring of the starting ether (2)
and aryl-boronic acids were well tolerated during
the reaction. The structures of these novel synthe-
sized compounds were characterized by Mass spec-
trometry, 1H-NMR, and 13C-NMR spectra.
DFT study
Oxidative addition
Recently, Huang and co-workers (21) proved
that B3LYP/6-31G (d) with pseudopotential on Pd
(LANL2DZ) is suitable to model the Suzuki cou-
pling reaction. In order to confirm the selectivity of
coupling at C-Br position over C-Cl, we started to
form two complexes Int1A (Br) and Int1B (Cl).
Figure 3. Biofilm inhibition, Hemolytic and Anti-thrombolytic activities of novel biaryls (3a-g)
Table 2. Biofilm inhibition (%) of Suzuki coupled compounds.
Entry Compounds Biofilm Inhibition%
1 3a 32.1 ± 0.25
2 3b 65.8 ± 0.34
3 3c 5.86 ± 0.05
4 3d 25.8 ± 0.12
5 3e 41.8 ± 0.21
6 3f 54.6 ± 0.25
7 3g 43.3 ± 0.43
8 Rifampicin 96.5 ± 0.65
The results are average ± S.D of three separate experiments p < 0.05
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Oxidative addition of palladium in the CñBr bond of
Int1A is much more favorable than in case of Int1B
(C-Cl). The oxidative addition transition state of
TS1A is located at a barrier of 2.78 kcal mol-1 from
Int1A, whereas the analogous transition state TS1B
of C-Cl coupling from Int1B lies at a much more
higher barrier of 9.79 kcal mol-1 as compared to
TS1A (Fig. 1). This is in complete agreement with
the experimental observation, where the products are
dominantly obtained as a result of oxidative addition
at C-Br bond. It is believed that the very low activa-
tion barrier for TS1A is due to the high reactivity of
C-Br bond over the C-Cl bond. The C-Cl (2.07¯ )
and C-Pd (1.98¯ ) bond lengths in TS1B are shorter
and stronger as compared to the C-Br (2.14¯ ) and C-
Pd (1.99¯ ) bonds in case of TS1A. The oxidative
addition step in both cases is exothermic by 17.2 and
17.25 kcal mol-1 from Int1A (Fig. 1) and Int1B (Fig.
2), respectively. Int2A and 2B (product of oxidative
addition) have almost equal stability. 
Transmetalation
Coordination of boronic acid with Int2A (C-
Br) and Int2B (C-Cl) generates Int3A and Int3B,
respectively. The intermediate Int3A, generated
from the cleavage of C-Br bond is highly exother-
mic by 212.63 kcal mol-1, however, the cleavage of
the PdñCl bond is very less exothermic by -1.31 kcal
mol-1 and Intermediate Int3B, generated from cleav-
age of the PdñCl bond, is almost on the similar ener-
gy level compared to Int1B. The transmetalation
transition state, translated form Int3A is exothermic
by -179.61 kcal mol-1 as compared to the starting
complex Int1A, whereas the analogous transition
state from the Int3B is located at activation barrier
of 1.86 kcal mol-1. Again the higher activation barri-
er of Pd-Cl transmetalation step is in accordance
with the experimental results, that the formation of a
product as a result of C-Cl bond coupling is negligi-
ble. The transmetalation product Int4A from TS3A
is exothermic by -182.67 kcal mol-1 and Int4B from
TS3B is exothermic by -32.27 kcal mol-1.
Reductive elimination
Very surprisingly, the reductive elimination
step in both cases turned out to be the one with the
very low activation barrier in the catalytic cycle for
both coupling products (rate limiting step). The
transition state TS5A from Int4A is exothermic and
located at a barrier of -199.22 kcal mol-1 as com-
pared to the Int1A. Similarly, the TS5B from Int4B
is also exothermic and located at -17.30 kcal mol-1.
From the overall computational results, it is con-
cluded that the observed selectivity of C-Br cou-
pling over C-Cl coupling may be attributed to the
low activation barrier of the oxidative addition step
of Int1A over Int1B, and to the associated with a
very low activation barrier of the reductive elimina-
tion step and is complete agreement with the exper-
imental products.
Pharmacology
Biofilm inhibition assay
The formation of biofilm by pathogenic bacte-
ria causes various fatal infections that may lead to
death in some worst cases. This film is an aggrega-
tion of bacterial cells, covered by a self-produced
polymeric material (22). Inhibition of formation by
novel biaryls (3a-g) was investigated against Esche-
richia coli, where the results revealed the moderate
activity of most of the compounds (Fig. 3, Table 
2). In particular, the compound 3b showed higher
activity (65.8%) as compared to other compounds
against E. coli, which might have its origin in the
two electron withdrawing fluoro groups attached
with the phenyl ring (23). On the other hand, other
biaryls exhibited moderate activity, when compared
with standard drug rifampicin. The biaryl 3c dis-
played the lowest activity 5.86%, which contains
electron donating methyl moiety. Overall, the results
reveal that all newly synthesized biaryls could be a
potential source of biofilm inhibition at high con-
centrations.
Hemolytic activity
The cytotoxicity of novel biaryls (3a-g) was
also studied in the present work. The biaryls 3e and
3f exhibited high hemolytic activity ~ 30.1 and
23.5%, respectively. Some of the novel biaryls viz.
3a, 3b, 3c, 3d, 3g exhibited hemolytic activity in a
safe range (below 10%) (Table 3, Fig. 3). From the
observed variations in the results of percentage lysis
of RBCs, it is concluded that the electron withdraw-
ing and electron donating substituents have a pro-
nounced effect on the hemolytic activity of the com-
pounds (24). Moreover, the cytotoxicity of the
derivatives viz. 3e and 3f can be optimized by doing
changes in the structure of molecules, for their prac-
tice as toxic compounds to inhibit the growth of
cancer cells (25, 26).
Anti-thrombolytic Activity
Blood clot formation is a severe problem that
hinders the blood circulation in the human body.
Thrombus obstructs the blood flow by blocking the
blood vessel, therefore hindering the tissues of nor-
mal blood flow and oxygen. These consequences led
to the necrosis of tissues in that area. Many drugs
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such as ticlopidine, heparin, clopidogrel, urokinase,
streptokinase and plasminogen activator (t-PA) have
been explored as the clot lysis agents. However, for
clinical practice, only some were found of potential-
ly beneficial (27-30). In this research work, we
investigated the anti-thrombolytic potential of novel
biaryl derivatives (3a-g). The results showed that the
compound 3f exhibited appreciable thrombolytic
activity (~ 42.5%), while 3g and 3d displayed mod-
erate % lysis ~ 23.4 and 21.2%, respectively. The
standard drug streptokinase, however, exhibited high
% lysis ~ 87.4%. The compounds 3b, 3a, and 3e
exhibited reasonable % lysis, while the compound 3c
was found inactive against clot lysis. The biaryls 3f,
3g, and 3d exhibited reasonable % lysis, which can
be attributed to -COCH3, -SCH3 and -OCH3 sub-
stituents attached to the aromatic system. Overall, it
can be seen that the anti-thrombolytic activity
showed by biaryls (3a-g) have a large effect from the
nature of attached substituents (23) (Table 4, Fig. 3).
CONCLUSIONS 
The present study reports the synthesis of vari-
ous novel biaryls (3a-g) with efficient yields under
mild optimized conditions. The density functional
theory studies revealed that the oxidative addition
and transmetalation steps are the rate controlling
steps. Energies of located transitions states of all
steps proved that C-Br coupling is preferred over C-
Cl coupling. The synthesized novel biaryls exhibit-
ed good biofilm inhibition, hemolytic and anti-
thrombolytic activities. From the observed varia-
tions in the results, it is concluded that the electron
withdrawing and donating substituents have a pro-
nounced effect on the biological activities of these
newly synthesized biaryl derivatives. Our experi-
mental results revealed that these compounds could
be a potential source of pharmaceutical agents at
higher concentrations.
Table 3. Hemolytic activity % of Suzuki coupled compounds.
Entry Compounds Hemolytic activity%
1 3a 2.64 ± 0.12
2 3b 5.76 ± 0.05
3 3c 6.32 ± 0.07
4 3d 1.32 ± 0.09
5 3e 30.1 ± 0.16
6 3f 23.5 ± 0.13
7 3g 1.59 ± 0.02
8 PBS 1.09 ± 0.01
9 Triton-X-100 98.4 ± 0.72
The results are average ± S.D of three separate experiments p < 0.05
Table 4. Anti-Thrombolytic activity % of Suzuki coupled compounds.
Entry Compounds % Thrombolysis
1 3a 12.5 ± 0.25
2 3b 12.9 ± 0.23
3 3c ----
4 3d 21.2 ± 0.19
5 3e 9.64 ± 0.09
6 3f 42.5 ± 0.45
7 3g 23.4 ± 0.21
9 Streptokinase 87.4 ± 0.83
The results are average ± S.D of three separate experiments p < 0.05
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